Cumulatively, these findings suggest that targeting LDL-induced upregulation of WAT NLRP3 inflammasome/ IL-1β secretion may reduce T2D risk factors; however, this remained to be established. The gene discussed is NLRP3; the disease is type 2 diabetes mellitus.